Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Raymond James Reiterates Strong Buy Rating on Edgewise Therapeutics (EWTX)
August 7, 2025 10:44 AM EDTRaymond James analyst Martin Auster reiterated a Strong Buy rating and $46.00 price target on Edgewise Therapeutics (NASDAQ: EWTX).
The analyst comments "EWTX reported 2Q financial results and provided a corporate update. Timing for key catalysts remains on track. We continue to believe that EWTX offers among the most attractive risk/reward skews in our coverage universe into CIRRUS-HCM Part D results (beginning in 4Q25); we reiterate our Strong Buy rating. Update from EDG-7500 Phase 2 CIRRUS-HCM Part D (12-week) expected in 4Q25. EWTX previously reported 4-week Phase 2 CIRRUS-HCM (Parts B/C) data in... More
